Effect of Hewei-Decoction on chronic atrophic gastritis and eradication of Helicobacter pylori.
OBJECTIVE
To demonstrate the effect of Hewei-Decoction (Decoction for regulating the stomach) on chronic atrophic gastritis (CAG) and eradication of Helicobacter pylori.


METHODS
Ninety patients with CAG entering the investigation were divided into six differentiation syndromes, based on their major symptoms and signs. Hewei-Decoction was taken by all the patients orally for 4 or 8 wk. The efficacy was assessed by both the composite accumulation of reduced scores of major symptoms and the eradication of H pylori. chi(2) test was used to compare the efficacy between H pylori-positive and negative cases, and to disclose the relationship between efficacy and eradication of H pylori.


RESULTS
In patients with six different syndrome types, the efficacy of Hewei-Decoction was 91.67% (11/12), 92.86% (13/14), 97.22% (35/36), 87.50% (14/16), 75.00% (6/8), 75.00% (3/4) respectively. The rate of highly efficacious was 58.33% (7/12), 50.00% (7/14), 77.78% (28/36), 62.50% (10/16), 12.50% (1/8) and 25.00% (1/4), respectively. The total efficacy was 91.11% (82/90), and the rate of highly efficacious was 60.00% (54/90). The eradication rate of H pylori was 67.86% (38/56). The therapeutic effect of Hewei-Decoction was better in H pylori positive cases than that in H pylori-negative cases with the total effect of 96.43% vs 82.35% (P<0.05). In 56 H pylori positive cases, the therapeutic effect was better in H pylori eradicated cases than that in H pylori- existent cases with the total effect of 97.37% vs 72.22% (P<0.01).


CONCLUSIONS
Hewei-Decoction is effective in most cases of all the syndrome types. The results indicate that eradication of H pylori is one of the important mechanisms for alleviation of symptoms and signs. Also, the decoction is efficacious in H pylori-negative cases.
Ji
Wan-Sheng
WS
Department of Internal Medicine, Weifang Medical College, Weifang 261042, Shandong Province, China. jiwsh@wfmc.edu.cn
Gao
Zhi-Xing
ZX
Wu
Kai-Chun
KC
Qiu
Jun-Wen
JW
Shi
Bing-Long
BL
Fan
Dai-Ming
DM
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001284:Atrophy; D002908:Chronic Disease; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D005260:Female; D005753:Gastric Mucosa / Q000473:pathology; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged
D004365:Drugs, Chinese Herbal
Am Fam Physician. 2004 Mar 1;69(5):1133-40
15023013
J Exp Med. 2003 Oct 20;198(8):1147-56
14568977
Zhongguo Zhong Xi Yi Jie He Za Zhi. 1995 Dec;15(12):719-23
8732138
Zhongguo Zhong Xi Yi Jie He Za Zhi. 1992 Oct;12(10):598-601, 580
1302541
Zhongguo Zhong Xi Yi Jie He Za Zhi. 1992 Oct;12(10):593-7, 579-80
1302540
Zhongguo Zhong Xi Yi Jie He Za Zhi. 1993 Oct;13(10):600-7, 580
8312696
Chin Med J (Engl). 1989 Oct;102(10):735-9
2517052
Can J Gastroenterol. 1999 Sep;13(7):571-9
10519954
J Tradit Chin Med. 1989 Dec;9(4):285-6
2630819
Scand J Gastroenterol. 2001 Jul;36(7):677-82
11444465
J Tradit Chin Med. 1999 Mar;19(1):10-5
10453577
Helicobacter. 2003;8(5):503-12
14535997
Zhong Xi Yi Jie He Za Zhi. 1989 Sep;9(9):537-9, 516
2598359
Zhongguo Zhong Xi Yi Jie He Za Zhi. 1993 Mar;13(3):144-6, 131-2
8339030
Public Health. 2001 Jul;115(4):282-5
11464301
Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):468-76
15006925
World J Gastroenterol. 2001 Dec;7(6):801-4
11854905
Geriatrics. 2000 Jun;55(6):44-9; quiz 50
10872345
J Tradit Chin Med. 1994 Dec;14(4):303-7
7877344